KWM advises UBS Wealth Management on $471 Million Oncology Impact Fund

Luye Pharma Group and AstraZeneca enter US$546 million agreement

News - UK

Luye Pharma Group (listed in Hong Kong) and AstraZeneca enter US$546 million agreement for rights to Seroquel and Seroquel XR in the UK, China and other international markets

King & Wood Mallesons’ cross-border team, advised Luye Pharma Hong Kong Limited (“Luye Pharma”) on its transaction signed with AstraZeneca relating to the sale and licence of the...

09 May 2018

King & Wood Mallesons represents the Kyrgyz Republic to settle US $75 million investor-state claim by Kazakhstan’s BTA Bank, with no admission of liability and no payment by the Kyrgyz Republic

These representations earned the Kyrgyz Republic a win in an investment treaty interpretation case named by Global Arbitration Review as among the ten 'most important decisions' of 2014...

28 March 2018

King & Wood Mallesons represents NextView Capital on its acquisition of a 19.89% equity interest in Bacanora Minerals Ltd.

King & Wood Mallesons represented NextView Capital, a leading Chinese institutional fund management group focused on new technologies and energy in its acquisition of a 19.89% equity interest...

18 December 2017

King & Wood Mallesons climbs the ladder in global law firm brand rankings

King & Wood Mallesons has improved its overall position in the 2017 Acritas Global Elite Law Firm Brand Index, ranking 13th.

12 October 2017

KWM obtains successful judgment for FXCM

The King & Wood Mallesons dispute resolution team in London has obtained another success in the Commercial Courts in favour of global FX broker FXCM.

23 August 2017

King & Wood Mallesons appoints EUME Managing Partner and welcomes new partners to EUME partnership

King & Wood Mallesons appoints its first EUME Managing Partner, and continues to strengthen the team by welcoming new partners

02 August 2017